Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Fazekas, F; Trinka, E; Kraus, J.
Tumefactive MS lesions under fingolimod: a case report and literature review.
Neurology. 2013; 81(19):1654-1658 Doi: 10.1212/01.wnl.0000435293.34351.11 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz

Fazekas Franz

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

To report about a possible association between fingolimod treatment and tumefactive demyelinating lesions (TDL) as seen in a patient developing repeated TDL on continued fingolimod therapy. We performed serial clinical and radiologic assessments and immunophenotyping of blood and CSF immune cells. We also present a literature review about recent similar cases. Clinical course and radiologic findings were consistent with diagnosis of TDL. Immune cell phenotyping showed pronounced shifts in the immune cell composition related to fingolimod treatment. In addition, we observed a subset of highly differentiated effector cells (CD45R0negCCR7neg) within the CD8+ T-cell population, which was about 2-fold enriched in the CSF compared to the peripheral blood. Our observations add further evidence for the development of atypical demyelinating lesions in some patients receiving fingolimod. These might be related to a treatment-associated shift in the immunopathology of specifically susceptible individuals.

Find related publications in this database (using NLM MeSH Indexing)

Adolescent -

Brain - pathology

Female -

Follow-Up Studies -

Humans -

Immunosuppressive Agents - therapeutic use

Magnetic Resonance Imaging -

Multiple Sclerosis - cerebrospinal fluid Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology

Oligoclonal Bands - cerebrospinal fluid

Plasma Exchange -

Propylene Glycols - therapeutic use

Sphingosine - analogs & derivatives Sphingosine - therapeutic use

© Med Uni Graz • Impressum